Literature DB >> 8943490

Beneficial effects of systemic immunoglobulin in experimental membranous nephropathy.

M Nangaku1, J Pippin, C A Richardson, M Schulze, B A Young, C E Alpers, K L Gordon, R J Johnson, W G Couser.   

Abstract

To test the hypothesis that systemic administration of immunoglobulin might reduce glomerular injury in membranous nephropathy through mechanisms involving inhibition of complement activation, we studied the passive Heymann nephritis (PHN) model of membranous nephropathy in rats. The daily administration of immunoglobulin goat IgG (600 mg/kg i.p.) reduced proteinuria by 52%. Quantitative immunohistochemical analysis showed that the glomerular deposition of C3c, an indicator of ongoing complement attack, and of C5b-9 was significantly decreased in the immunoglobulin treated group, while deposition of anti-Fx1A was not affected. Electron microscopic analysis demonstrated that the extent of subepithelial immune complexes did not appreciably differ between treated and control animals. Systemic complement levels were not altered by immunoglobulin treatment. These data suggest that the reduction in proteinuria that resulted from systemic immunoglobulin administration was mediated by modifying the effect of complement induced glomerular injury. This interpretation was further supported by in vitro data that documented a significant reduction in C5b-9 induced glomerular epithelial cell lysis in the presence of both goat and rat IgG. These results indicate that systemic administration of immunoglobulin can substantially reduce ongoing complement activation in the glomerulus in PHN rats and that this effect is associated with a significant reduction in glomerular injury.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8943490     DOI: 10.1038/ki.1996.529

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  6 in total

Review 1.  Experimental membranous nephropathy redux.

Authors:  Andrey V Cybulsky; Richard J Quigg; David J Salant
Journal:  Am J Physiol Renal Physiol       Date:  2005-10

2.  The efficiency of intraperitoneal high-dose immunoglobulin in experimental nephrotic syndrome.

Authors:  Seyhan Erisir; Halide Akbas; Mustafa Koyun; Sema Akman
Journal:  Pediatr Nephrol       Date:  2005-10-27       Impact factor: 3.714

3.  Intravenous immunoglobulin (IVIG) attenuates antibody binding in acute haemorrhagic immunopneumonitis in a rat model of complement-dependent lung injury.

Authors:  M Dantas; R S Costa; J E Barbosa; M S Graeff; W Sarti; I F De Carvalho
Journal:  Clin Exp Immunol       Date:  2000-07       Impact factor: 4.330

4.  Down-regulation of pathogenic autoantibody response in a slowly progressive Heymann nephritis kidney disease model.

Authors:  Arpad Z Barabas; Chad D Cole; Arpad D Barabas; Rene Lafreniere
Journal:  Int J Exp Pathol       Date:  2004-12       Impact factor: 1.925

5.  Production of a new model of slowly progressive Heymann nephritis.

Authors:  Arpad Z Barabas; Chad D Cole; Arpad D Barabas; Rene Lafreniere
Journal:  Int J Exp Pathol       Date:  2003-12       Impact factor: 1.925

6.  Novel approach to specific growth factor inhibition in vivo: antagonism of platelet-derived growth factor in glomerulonephritis by aptamers.

Authors:  J Floege; T Ostendorf; U Janssen; M Burg; H H Radeke; C Vargeese; S C Gill; L S Green; N Janjić
Journal:  Am J Pathol       Date:  1999-01       Impact factor: 4.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.